Meta AnalysisID 4022
蛋白酶抑制剂降低HIV相关神经认知障碍风险的研究
CRD42020157255
How does protease inhibitors impact on risk of HIV associated neurocognitive disorders compared to others antirretroviral drugs?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4022
- Evidence Id
- 12580
- Core Evidence Id
- 12580
- Source Meta Analysis Id
- 3980
- Herb2 Meta Analysis Id
- HBMA003980
- Crd Id
- CRD42020157255
- Title
- Protease inhibitors to reduce the risk of HIV-associated neurocognitive disorder
- Review Question
- How does protease inhibitors impact on risk of HIV associated neurocognitive disorders compared to others antirretroviral drugs?
- Study Type Included
- All comparisons in randomized and no randomized controlled clinical trials and observational cohort studies.
- Condition Being Studied
- HIV-associated neurocognitive disorder
- Participant
- Patients are older than 13 years, of both sexes, who are in highly effective antiretroviral treatment and achieve undetectable viral load, without infections of the central nervous system due to opportunistic germs, without neurocognitive alterations prior to infection by human immunodeficiency virus.
- Animal
- Human Disease Modelled
- Intervention
- Treatment with protease inhibitors: lopinavir / ritonavir 200/50 mg 2 tab every 12 hours; atazanavir 300 mg daily with or without ritonavir 100 mg daily; darunavir 600 mg vo every 12 hours or 800 mg vo once a day with ritonavir 100 mg vo day all alone or in triple therapy with nucleoside analogue reverse transcriptase inhibitors.
- Comparator Control
- Treatment with non-nucleoside reverse transcriptase inhibitors: Efavirenz 600 mg daily or nevirapine 200 mg daily every 12 hours Treatment with integrase inhibitors: raltegravir 400 mg every 12 hours, dolutegravir 50 mg daily, elvitegravir 150 mg daily.
- Main Outcome
- Neurocognitive disorder associated with HIV in its mild, moderate or severe forms. Measured with batteries from neuropsychological studies and / or nuclear magnetic imaging Measures of effect At least 24 weeks of follow up. OR, HR, or RR
- Outcome Measure
- Additional Outcome
- Virological suppression: undetectable viral load. (PCR) Adverse effects: gastrointestinal, psychiatric disorders. Mortality Immunological reconstitution: increase in the CD4 count of 50 or more cells in relation to the baseline measurement. Cytometry Virological failure: viral load detectable in more than two measurements despite adherence to ART. Viral load is measured by polymerase chain reaction. Cardiovascular risk. Calculation using Framingham scale application. Measures of effect At least 24 weeks of follow up. OR, HR, or RR
- Study Method
- Intervention, Meta-analysis, Prognostic, Systematic review
- Keyword
- Humans
- Contact
- Hernan Dario Vergara Samur [email protected]
- Organisational Affiliation
- NONE NONE
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Not other versions of this systematic review we were found
- Published Protocol
- Review Type
- Language
- English, Spanish
- Country
- Colombia
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-02-10
- Registration Date
- 2020-04-28
- Anticipated Start Date
- 2019-11-04
- Anticipated Completion Date
- 2020-03-18
- Title Cn
- 蛋白酶抑制剂降低HIV相关神经认知障碍风险的研究
- Title En
- Protease inhibitors to reduce the risk of HIV-associated neurocognitive disorder
- Bilingual Status
- complete